Hemophilia A has been widely studied, and gene therapy has been a clinical approach carried out in animal models and some human clinical trials. Since standard approaches for treating hemophilia A have yet to be successful, alternative novel strategies are thought to be needed. One such approach has been developed in this grant during the past funding cycle, and has focused on expressing FVIII in megakaryo?? cytes and endothelial cells. The natural interactions between VWF and FVIII might facilitate the expression of FVIII and make use of these interactions clinically. This grant has three aims that explore the interactions between FVIII and VWF, and how this could lead to strategies to optimize gene therapy for hemophilia. Even more exciting, this approach might be advantageous for hemophilic patients who have developed treatment-altering inhibitory antibodies.
Aim 1 will study the local and systemic effect of VWF complexes with FVIII in the presence of specific FVIII inhibitory antibodies, and determine the safety of delivering FVIII in platelets.
Aim 2 will study the delivery of FVIII in platelets, and determine its efficacy in a large animal model of hemophilia.
Aim 3 will study a gene therapy approach in which FVIII is synthesized in and stored by endothelial cells, and whether endothelial cells normally synthesize FVIII. These models will dissect the contribution of VWF to the therapeutic efficacy of FVIII in the presence of inhibitory antibodies. Since the murine and canine models are less severe clinical models than the human disorder, and because dog platelets normally lack VWF. another animal model with platelet VWF is needed. The ovine model of hemophilia provides just such a model characterized by clinical severe bleeding, normal VWF in its platelets like humans, and most uniquely, the fetal ovine model has been demonstrated to permit long-term, life-long chimeric expression of human hematopoietic cells where human megakaryocytes/platelets, transduced to express and store FVIII, can be studied for safety and clinical efficacy. These studies will provide much additional critical safety and efficacy on this novel approach to gene therapy for hemophilia and provide a pre-clinical model of highest relevance before considering human trials.

Public Health Relevance

This grant addresses a novel strategy to carry out gene therapy of hemophilia, a severe clinical bleeding disorder. While most studies have targeted liver cells, our unique approach will targets the expressed FVIII to endothelial cells or megakaryocytes - cells that normally synthesize and store VWF. These approaches may not only treat patients with hemophilia, but also treat those patients that have high-titer inhibitory antibodies that would normally mitigate against traditional replacement therapy, or even traditional gene therapy approaches to replace FVIII in plasma.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL044612-23
Application #
8434893
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
23
Fiscal Year
2013
Total Cost
$406,880
Indirect Cost
$110,043
Name
Bloodcenter of Wisconsin, Inc.
Department
Type
DUNS #
057163172
City
Milwaukee
State
WI
Country
United States
Zip Code
53233
Fahs, Scot A; Hille, Matthew T; Shi, Qizhen et al. (2014) A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123:3706-13
Shi, Qizhen; Kuether, Erin L; Chen, Yingyu et al. (2014) Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. Blood 123:395-403
Kanaji, S; Fahs, S A; Ware, J et al. (2014) Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome. J Thromb Haemost 12:1726-32
Zheng, Yongwei; Wang, Alexander W; Yu, Mei et al. (2014) B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia. Blood 123:931-4
Elbatarny, M; Mollah, S; Grabell, J et al. (2014) Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia 20:831-5
Weiler, Hartmut (2014) Inflammation-associated activation of coagulation and immune regulation by the protein C pathway. Thromb Res 133 Suppl 1:S32-4
Brott, David A; Katein, Anne; Thomas, Heath et al. (2014) Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury. Toxicol Pathol 42:672-83
Zheng, Yongwei; Yu, Mei; Podd, Andrew et al. (2013) Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood 121:3484-92
Qi, Xiaopeng; Hong, Jessie; Chaves, Lee et al. (2013) Antagonistic regulation by the transcription factors C/EBP* and MITF specifies basophil and mast cell fates. Immunity 39:97-110
Tourdot, Benjamin E; Brenner, Michelle K; Keough, Kathleen C et al. (2013) Immunoreceptor tyrosine-based inhibitory motif (ITIM)-mediated inhibitory signaling is regulated by sequential phosphorylation mediated by distinct nonreceptor tyrosine kinases: a case study involving PECAM-1. Biochemistry 52:2597-608

Showing the most recent 10 out of 176 publications